Jazz Pharmaceuticals
JAZZ
Market cap $7.08B

114.63 USD

-1.02

0.88%

At close Oct 17, 4:00 PM EDT

After hours

114.63

+0.00

0.00%

1 day

-0.88%

5 days

5.96%

1 month

2.76%

3 months

6.13%

6 months

7.03%

Year to date

-9.69%

1 year

-13.64%

5 years

-5.37%

About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Employees: 2,800

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 11 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

62% more call options, than puts

Call options by funds: $27.7M | Put options by funds: $17.2M

5% less repeat investments, than reductions

Existing positions increased: 156 | Existing positions reduced: 164

3.18% less ownership

Funds ownership: 94.32% [Q1] → 91.14% (-3.18%) [Q2]

5% less funds holding

Funds holding: 471 [Q1] → 446 (-25) [Q2]

13% less capital invested

Capital invested by funds: $7.08B [Q1] → $6.14B (-$945M) [Q2]

14% less funds holding in top 10

Funds holding in top 10: 7 [Q1] → 6 (-1) [Q2]

29% less first-time investments, than exits

New positions opened: 61 | Existing positions closed: 86

See Fund Rankings

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$120

5%

upside

Avg. target

$171

49%

upside

High target

$205

79%

upside

11 analyst ratings

10 positive

91%

1 neutral

9%

0 negative

0%

RBC Capital Gregory Renza 56% 1-year accuracy 39 / 70 met price target	53%upside $175	Outperform Maintained	4 Oct 2024
Needham Ami Fadia 58% 1-year accuracy 73 / 125 met price target	79%upside $205	Buy Reiterated	10 Sept 2024
Cantor Fitzgerald Charles Duncan 45% 1-year accuracy 31 / 69 met price target	22%upside $140	Overweight Reiterated	9 Sept 2024
JP Morgan Jessica Fye 64% 1-year accuracy 25 / 39 met price target	76%upside $202	Overweight Maintained	19 Aug 2024
Cantor Fitzgerald Charles Duncan 45% 1-year accuracy 31 / 69 met price target	22%upside $140	Overweight Reiterated	1 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about JAZZ published over the past 30 days

Zacks Investment Research

Wall Street Analysts Think Jazz (JAZZ) Could Surge 51.8%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 51.8% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Jazz (JAZZ) Could Surge 51.8%: Read This Before Placing a Bet

Zacks Investment Research

Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?

Zacks Investment Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Zacks Investment Research

JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study

Data from a late-stage study showed that Jazz's Zepzelca, combined with Roche's Tecentriq, improved survival rates in certain patients with small-cell lung cancer.

JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. The partial legal win against Avadel helps protect Jazz's market position in idiopathic hypersomnia through 2036 and Jazz should also receive royalties on net sales of Lumryz. The unexpected phase 3 trial win of Zepzelca in combination with Tecentriq could add more than $400-500 million in annual net sales by the end of the decade.

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer

Jazz Pharmaceuticals plc JAZZ revealed topline results from the Phase 3 clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG's RHHBY atezolizumab (Tecentriq) compared to atezolizumab alone when administered as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab.

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz plans to submit supplemental New Drug Application in first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC DUBLIN , Oct. 15, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of Zepzelca and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review facility (IRF), compared to treatment with atezolizumab alone.

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market

Jazz Pharmaceuticals (JAZZ, Financial), a leading player in the narcolepsy market, is expanding its reach into other markets such as the non-small cell lung cancer (NSCLC) market by preparing a new biliary tract cancer drug; Zanidatamab.

Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market

Zacks Investment Research

Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock

Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.

Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock

Zacks Investment Research

Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?

See News Rankings

Charts implemented using Lightweight Charts™